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GLOBAL DENGUE EPIDEMIOLOGY TRENDS
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Dengue disease is the most rapidly spreading mosquito-borne viral 
disease. The four dengue virus serotypes (DENV 1, 2, 3, and 4) are 
transmitted by mosquitoes of the genus Aedes Infection by each serotype 
is considered to induce serotype-specific lifetime immunity. Any of the 
serotypes can cause severe dengue and fatal disease.
Worldwide, between 2.5 and 3.6 billion people, over 50% of the 
population, are at risk, in over 125 endemic countries.
An estimated 50 to 270 million dengue infections occur every year, 
of which two million cases evolve to severe Dengue Hemorrhagic Fever, 
and 21 000 would result in death1,2 .
Determinant factors of dengue global epidemiology trends include, 
but are not limited to: 1) demographic changes including population 
growth, economical trends in tropical countries and land use patterns; 
2) increased urban population size and density due to rural to urban 
migration 3) modern transportation with increased movement of people, 
commodities, animals, vectors and pathogens; and 4) changes in public 
health policies and infrastructures3. 
The geographic spread of both the mosquito vectors and the viruses 
has led to a global resurgence of epidemic dengue disease and emergence 
of severe forms in the past 25 years4. From nine dengue-reporting countries 
in the 1950s, dengue is currently a public health concern in over 100 
countries5. The four dengue virus serotypes are found in tropical and sub-
tropical regions around the world. Dengue is endemic in Asia, the Pacific 
area, Africa, and Latin America (including the Caribbean)6.
South-East Asia Region (SEAR) and the Western Pacific Regions bear 
nearly 75% of the dengue global disease burden. In 2010, 187,333 dengue 
cases were reported to the WHO SEAR office; and 354,009 cases were 
reported to the WHO Western Pacific Region, including 1,075 deaths.
An increase in the amplitude and the frequency of epidemics was 
observed in Latin America in recent years. Brazil, Colombia, Honduras, 
Mexico, Puerto Rico, and Venezuela are among the countries reporting the 
highest number of dengue cases to the Pan American Health Organization 
(PAHO). In 2010, 1,663,276 dengue cases were reported to PAHO 
including 1,194 deaths7.
After decades of absence in the US, dengue has recently emerged 
with dengue cases locally acquired8 and the establishment of endemicity 
in US tropical territories (e.g., Puerto Rico)9. 
Dengue does not naturally occur in continental Europe but conditions 
are suitable for transmission with increasing risk for transmission (e.g., 
establishment of Ae. albopictus mosquito and viremic travelers)10,11. 
In Africa, the incidence of dengue is largely unknown due to sparse 
surveillance data with cases and outbreaks not reported to WHO12. 
However, epidemic dengue fever caused by all four serotypes has been 
documented in Africa since 1980, with 22 countries reporting sporadic 
cases. High prevalence of antibody to dengue virus in limited serologic 
surveys suggests endemic dengue virus infection in many parts of Africa13.
While geographical expansion of dengue and its vector are evident, 
the true burden of disease is underestimated due to constraints inherent to 
public health surveillance systems and the challenges specific to dengue. 
Lack of uniformity in dengue case definitions, in diagnosis ascertainment, 
in laboratory capacity, and the diversity of public health practices in 
each country, all affect the interpretation of the evidence generated by 
dengue surveillance systems14. Most dengue cases are asymptomatic 
and go undetected, and Persons with mild illness may not seek medical 
attention. Consequently the actual number of dengue disease cases is 
underreported and burden of disease is substantially underestimated15. 
In the absence of an effective vaccine, public health systems focus 
on the early identification and early response to outbreaks. This is of 
particular importance given the unpredictability of dengue together 
with the lack of sustainable prevention or control measures. In such 
an environment, public health programs often neglect the importance 
of accurately estimating the burden of disease or the impact of control 
efforts. However, once a disease becomes vaccine preventable, 
surveillance systems become key tools to assess the performance of 
vaccination programs. Ways of improving surveillance of vaccine-
preventable diseases include encouraging reporting; ensuring adequate 
investigation of suspected cases; improving easiness and completeness of 
reporting mechanisms; strengthening overall surveillance infrastructure 
(e.g. laboratory capacity) and implementing enhanced surveillance 
activities (e.g. sentinel surveillance and primary care and hospital levels).
In summary, the global trends of dengue disease epidemiology are 
characterized by a rapidly expanding geographic distribution of vector 
infestation, the risk of infection, and disease transmission, despite ongoing 
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control efforts. An increased frequency and magnitude of epidemics with 
significant levels of hospitalization and a marked increased risk for severe 
forms of dengue are associated with the continual circulation of the four 
dengue virus serotypes. Dengue is therefore an increasingly global public 
health concern, characterized by unpredictable epidemics, and for which 
no sustainable control measures currently exist.
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